文献速递胸部肿瘤放疗放疗物理与技术

早期非小细胞肺癌单次与多次立体定向消融放疗的人群分析

Population-based analysis of single-fraction versus multi-fraction stereotactic ablative radiotherapy for early-stage non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2026-09-26

该研究基于加拿大不列颠哥伦比亚省人群数据,回顾性比较外周T1-2N0非小细胞肺癌患者接受单次(30或34 Gy)与多次(48 Gy/4次或54 Gy/3次)立体定向消融放疗的疗效与毒性。共纳入778例患者814个病灶,中位随访25.8个月,两组2年局部失败率、总生存率及毒性均无统计学显著差异。

要点

  • 单次与多次SABR的2年局部失败率分别为3.5%与4.8%,无显著差异。
  • 两组2年总生存率分别为79.3%与79.4%,无显著差异。
  • 单次SABR未预测更差的局部失败、生存或毒性。

核心结论

  • 单次与多次SABR在局部失败、总生存和毒性方面未观察到统计学显著差异。
  • 单次SABR因便利且成本效益好,应考虑用于该患者人群。

研究设计与样本

  • 基于加拿大不列颠哥伦比亚省人群的回顾性研究。
  • 纳入2021年1月至2024年8月接受单次SABR(30 Gy或34 Gy)或多次SABR(48 Gy/4次或54 Gy/3次)的外周T1-2N0非小细胞肺癌患者。
  • 共814个病灶来自778例患者,其中单次SABR 283个,多次SABR 531个。
  • 局部失败和总生存采用Kaplan-Meier法及以死亡为竞争风险的累积发生率函数估计。
  • 毒性按CTCAE v5.0分级,采用Fine-Gray和Cox回归分析变量,二元逻辑回归评估胸壁毒性预测因素。

主要发现

  • 中位随访25.8个月(四分位距18.8-36.6)。
  • 2年局部失败率单次SABR为3.5%,多次SABR为4.8%(p=0.11)。
  • 2年总生存率单次SABR为79.3%,多次SABR为79.4%(p=0.62)。
  • 任何2级毒性发生率单次SABR为11.5%,多次SABR为12.4%(p=0.13)。
  • 任何3-5级毒性发生率单次SABR为1.5%,多次SABR为3.9%(p=0.08);2级及以上胸壁毒性均为5.0%(p=0.98)。

关键数值与推荐

  • 单次SABR方案为30 Gy或34 Gy。
  • 多次SABR方案为48 Gy/4次或54 Gy/3次。
  • 单次SABR未预测更差的局部失败、总生存、任何2级及以上毒性或2级及以上胸壁毒性。

临床怎么用

  • 对于外周T1-2N0非小细胞肺癌,单次SABR可作为便利且成本效益好的治疗选择。
  • 单次与多次SABR的疗效和毒性相似,决策时可结合患者便利性和资源考虑。

局限性

  • 回顾性研究设计。
  • 单中心人群数据,中位随访25.8个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Optimal dose fractionation of stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer (NSCLC) remains unclear. This population-based study compares outcomes and toxicities of single-fraction (SF) versus multi-fraction (MF) SABR. METHODS: All patients in British Columbia, Canada with peripheral T1-2N0 NSCLC treated with either SF-SABR (30 Gy or 34 Gy) or MF-SABR (48 Gy/4 or 54 Gy/3 fractions) between January 2021 and August 2024 were retrospectively reviewed. Local failure (LF) and overall survival (OS) were estimated using Kaplan-Meier method and cumulative incidence functions with death as a competing risk. Toxicity was graded per Common Terminology Criteria for Adverse Events version 5.0. Fine-Gray and Cox regression analyses were used to identify variables associated with LF and OS, respectively. Binary logistic regression was used to assess predictors of chest wall toxicity (CWT). RESULTS: A total of 814 lesions in 778 patients were included (SF-SABR 283 and MF-SABR 531). Median follow-up was 25.8 months (interquartile range, 18.8-36.6). No significant differences were observed in 2-year LF (3.5% vs. 4.8%, p = 0.11) or 2-year OS (79.3% vs. 79.4%, p = 0.62). There were no differences in any grade 2 toxicity (11.5% vs. 12.4%, p = 0.13), any grade 3-5 toxicity (1.5% vs. 3.9%, p = 0.08), or grade 2 + CWT (5.0% vs. 5.0%, p = 0.98). SF-SABR alone did not predict worse LF, OS, any grade 2 + toxicity, or grade 2 + CWT. CONCLUSION: No statistically significant differences were observed in LF, OS, or toxicity between SF-SABR and MF-SABR. SF-SABR should be considered for this patient population as it is convenient and cost-efficient.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Aguirre-Meneses KA, Baker S, Callueng JM, et al. Population-based analysis of single-fraction versus multi-fraction stereotactic ablative radiotherapy for early-stage non-small cell lung cancer. Radiother Oncol. 2026. PMID: 42800679. doi:10.1016/j.radonc.2026.111798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。